Jim Cramer, host of CNBC’s Mad Money, told investors on Monday to stop chasing the market’s biggest winners and start looking at what everyone else is ignoring.
Cramer said stocks making “parabolic” moves, especially in tech and AI, are dangerous to buy. He said when he buys into those kinds of moves, he tends to lose money.
Instead of chasing stocks like Intel or Advanced Micro Devices, Cramer said he is doing the opposite. He is buying quality companies that have sold off and fallen out of favor with the market.
His CNBC Investing Club Charitable Trust recently bought shares of Johnson & Johnson while the stock was still dropping. The health-care sector is currently the worst-performing sector in the S&P 500 this year.
Cramer said Johnson & Johnson is now his favorite drug stock, a position previously held by Eli Lilly. He cited the company’s drug pipeline and its ongoing business transformation as reasons for his confidence.
Johnson & Johnson, JNJ
Johnson & Johnson has been shedding slower-growing divisions and focusing more on pharmaceutical research. The company has multiple drugs in late-stage development and several recent approvals.
Cramer said recent weakness in the stock has been driven mostly by noise, particularly concerns around talc lawsuits. He argued those concerns have overshadowed real progress inside the company.
Cramer’s broader point was about how investors build their portfolios. He said owning only the hottest names is risky because sentiment can shift quickly.
If one area of the market falls out of favor, owning some undervalued names means you still have something working. Cramer said this was a lesson he learned at Goldman Sachs.
Health care stocks have been hit hard in 2025. Johnson & Johnson shares are down over the past year, with the stock falling around 1.57% in recent sessions alongside continued sector pressure.
The post Jim Cramer Warns Against Chasing Parabolic Stocks – Here’s Where He’s Putting His Money appeared first on CoinCentral.

